| D008875 |
Middle Aged |
An adult aged 45 - 64 years. |
Middle Age |
|
| D010078 |
Oxazines |
Six-membered heterocycles containing an oxygen and a nitrogen. |
|
|
| D005260 |
Female |
|
Females |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000328 |
Adult |
A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. |
Adults |
|
| D000368 |
Aged |
A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. |
Elderly |
|
| D012702 |
Serotonin Antagonists |
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. |
5-HT Antagonist,5-HT Antagonists,5-Hydroxytryptamine Antagonist,5-Hydroxytryptamine Antagonists,Antiserotonergic Agent,Antiserotonergic Agents,Serotonin Antagonist,Serotonin Blockader,Serotonin Blockaders,Serotonin Receptor Antagonist,Serotonin Receptor Blocker,Antagonists, 5-HT,Antagonists, 5-Hydroxytryptamine,Antagonists, Serotonin,Serotonin Receptor Antagonists,Serotonin Receptor Blockers,5 HT Antagonist,5 HT Antagonists,5 Hydroxytryptamine Antagonist,5 Hydroxytryptamine Antagonists,Agent, Antiserotonergic,Agents, Antiserotonergic,Antagonist, 5-HT,Antagonist, 5-Hydroxytryptamine,Antagonist, Serotonin,Antagonist, Serotonin Receptor,Antagonists, 5 HT,Antagonists, 5 Hydroxytryptamine,Antagonists, Serotonin Receptor,Blockader, Serotonin,Blockaders, Serotonin,Blocker, Serotonin Receptor,Blockers, Serotonin Receptor,Receptor Antagonist, Serotonin,Receptor Antagonists, Serotonin,Receptor Blocker, Serotonin,Receptor Blockers, Serotonin |
|
| D013509 |
Gynecologic Surgical Procedures |
Surgery performed on the female genitalia. |
Gynecologic Surgery,Gynecologic Surgical Procedure,Gynecological Surgical Procedure,Procedure, Gynecologic Surgical,Procedures, Gynecologic Surgical,Surgery, Gynecological,Surgical Procedure, Gynecologic,Surgical Procedures, Gynecologic,Gynecologic Surgeries,Gynecological Surgeries,Gynecological Surgery,Gynecological Surgical Procedures,Procedure, Gynecological Surgical,Procedures, Gynecological Surgical,Surgeries, Gynecologic,Surgeries, Gynecological,Surgery, Gynecologic,Surgical Procedure, Gynecological,Surgical Procedures, Gynecological |
|
| D016896 |
Treatment Outcome |
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. |
Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes |
|
| D017294 |
Ondansetron |
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. |
4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-,Zofran ODT,GR-38032F,GR38032F,Ondansetron Hydrochloride,Ondansetron Monohydrochloride,Ondansetron Monohydrochloride Dihydrate,Ondansetron, (+,-)-Isomer,Ondansetron, (R)-Isomer,Ondansetron, (S)-Isomer,SN-307,Zofran,Dihydrate, Ondansetron Monohydrochloride,GR 38032F,Hydrochloride, Ondansetron,Monohydrochloride Dihydrate, Ondansetron,Monohydrochloride, Ondansetron,ODT, Zofran,SN 307,SN307 |
|